These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 38788547

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.
    Horn LA, Long TM, Atkinson R, Clements V, Ostrand-Rosenberg S.
    Cancer Immunol Res; 2018 Jan; 6(1):59-68. PubMed ID: 29122838
    [Abstract] [Full Text] [Related]

  • 23. [T cell-based immunotherapies in solid tumors].
    Baulu E, Dougé A, Chuvin N, Bay JO, Depil S.
    Bull Cancer; 2021 Oct; 108(10S):S96-S108. PubMed ID: 34920813
    [Abstract] [Full Text] [Related]

  • 24. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
    Cheng Z, Wei R, Ma Q, Shi L, He F, Shi Z, Jin T, Xie R, Wei B, Chen J, Fang H, Han X, Rohrs JA, Bryson P, Liu Y, Li QJ, Zhu B, Wang P.
    Mol Ther; 2018 Apr 04; 26(4):976-985. PubMed ID: 29503204
    [Abstract] [Full Text] [Related]

  • 25. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
    Nakajima M, Sakoda Y, Adachi K, Nagano H, Tamada K.
    Cancer Sci; 2019 Oct 04; 110(10):3079-3088. PubMed ID: 31432594
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation.
    Halim L, Das KK, Larcombe-Young D, Ajina A, Candelli A, Benjamin R, Dillon R, Davies DM, Maher J.
    Front Immunol; 2022 Oct 04; 13():836549. PubMed ID: 35222427
    [Abstract] [Full Text] [Related]

  • 28. PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15.
    Kim KH, Kim HK, Kim HD, Kim CG, Lee H, Han JW, Choi SJ, Jeong S, Jeon M, Kim H, Koh J, Ku BM, Park SH, Ahn MJ, Shin EC.
    Cell Mol Immunol; 2021 Feb 04; 18(2):385-397. PubMed ID: 32332901
    [Abstract] [Full Text] [Related]

  • 29. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
    Qin JS, Johnstone TG, Baturevych A, Hause RJ, Ragan SP, Clouser CR, Jones JC, Ponce R, Krejsa CM, Salmon RA, Ports MO.
    J Immunother; 2020 May 04; 43(4):107-120. PubMed ID: 31899702
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ.
    Cancer Res; 2006 Nov 15; 66(22):10995-1004. PubMed ID: 17108138
    [Abstract] [Full Text] [Related]

  • 32. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
    Yuan X, Sun Z, Yuan Q, Hou W, Liang Q, Wang Y, Mo W, Wang H, Yu M.
    Invest New Drugs; 2021 Feb 15; 39(1):34-51. PubMed ID: 32772342
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Optimization of CD19 chimeric antigen receptor T cell establishment and observation of the killing effect in vitro and in vivo].
    Ren CX, Chen XX, Zhao L, Tian Y, Xu KL, Zhao K.
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jun 14; 43(6):506-512. PubMed ID: 35968595
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy.
    Fernandez-Poma SM, Salas-Benito D, Lozano T, Casares N, Riezu-Boj JI, Mancheño U, Elizalde E, Alignani D, Zubeldia N, Otano I, Conde E, Sarobe P, Lasarte JJ, Hervas-Stubbs S.
    Cancer Res; 2017 Jul 01; 77(13):3672-3684. PubMed ID: 28522749
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.